(Q37327047)

English

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

scientific article published on 14 May 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years (English)

1 reference

Europe PubMed Central

19 August 2017

type-1 diabetes

0 references

0 references

1 reference

based on heuristic

inferred from title

Vicki Seyfert-Margolis

10

object named as

Vicki Seyfert-Margolis

1 reference

Europe PubMed Central

19 August 2017

Jennifer M Puck

4

object named as

Jennifer Puck

1 reference

Europe PubMed Central

19 August 2017

1

object named as

Kevan C Herold

1 reference

Europe PubMed Central

19 August 2017

Carla J Greenbaum

3

object named as

Carla Greenbaum

1 reference

Europe PubMed Central

19 August 2017

author name string

Stephen Gitelman

2

1 reference

Europe PubMed Central

19 August 2017

William Hagopian

5

1 reference

Europe PubMed Central

19 August 2017

Peter Gottlieb

6

1 reference

Europe PubMed Central

19 August 2017

Peter Sayre

7

1 reference

Europe PubMed Central

19 August 2017

Peter Bianchine

8

1 reference

Europe PubMed Central

19 August 2017

Emelita Wong

9

1 reference

Europe PubMed Central

19 August 2017

Kasia Bourcier

11

1 reference

Europe PubMed Central

19 August 2017

Jeffrey A Bluestone

12

1 reference

Europe PubMed Central

19 August 2017

Immune Tolerance Network ITN007AI Study Group

13

1 reference

Europe PubMed Central

19 August 2017

publication date

14 May 2009

1 reference

Europe PubMed Central

19 August 2017

Clinical Immunology

1 reference

Europe PubMed Central

19 August 2017

132

1 reference

Europe PubMed Central

19 August 2017

166-173

1 reference

Europe PubMed Central

19 August 2017

2

1 reference

Europe PubMed Central

19 August 2017

Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

6 September 2017

Growth hormone enhances thymic function in HIV-1-infected adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

6 September 2017

Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

6 September 2017

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

6 September 2017

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

6 September 2017

Development of population-based newborn screening for severe combined immunodeficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

6 September 2017

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

6 September 2017

Multiparameter evaluation of human thymic function: interpretations and caveats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

14 September 2017

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

14 September 2017

TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

26 June 2018

Redefining the clinical remission period in children with type 1 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

2 September 2018

C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

2 September 2018

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

2 September 2018

Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

2 September 2018

In vitro characterization of five humanized OKT3 effector function variant antibodies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

2 September 2018

Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

2 September 2018

Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2735402

20 October 2018

Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19443276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/19443276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/19443276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19443276

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.CLIM.2009.04.007

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37327047&oldid=1700647400"